KW-6356

Kyowa Kirin, Inc. · Phase 2 active Small molecule

At a glance

Generic name	KW-6356
Sponsor	Kyowa Kirin, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite (PHASE1)
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356 (PHASE1)
A Through QT/QTc Study of KW-6356 (PHASE1)
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations (PHASE2)
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (PHASE1)
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin (PHASE1)
A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects (PHASE1)
A Study of KW-6356 in Subjects With Early Parkinson's Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KW-6356 CI brief — competitive landscape report
KW-6356 updates RSS · CI watch RSS
Kyowa Kirin, Inc. portfolio CI